Functional differences in epigenetic modulators - Superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies

Journal of Medicinal Chemistry

Volumn 50, Issue 13, 2007, Pages 3054-3061

  Kozikowski, Alan P ^a   Chen, Yufeng ^a   Gaysin, Arsen ^a   Chen, Bin ^a   D'Annibale, Melissa A ^b   Suto, Carla M ^c   Langley, Brett C ^b,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^c Amphora Discovery Corporation   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MERCAPTOACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS;

ACETAMIDES; ACETYLATION; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; ISOENZYMES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 34347224016     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070178x     Document Type: Article

References (32)

1. Marks, P. A.; Dokmanovic, M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin. Invest. Drugs 2005, 14, 1497-1511.
2. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
3. Kurdistani, S. K.; Grunstein, M. Histone acetylation and deacetylation in yeast. Nat. Rev. Mol. Cell Biol. 2003, 4, 276-284.
4. Struhl, K.; Moqtaderi, Z. The TAFs in the HAT. Cell 1998, 94, 1-4.
5. Wolffe, A. P.; Guschin, D. Review: Chromatin structural features and targets that regulate transcription. J. Struct. Biol. 2000, 129, 102-122.
6. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92, 1210-1216.
7. Carducci, M. A.; Gilbert, J.; Bowling, M. K.; Noe, D.; Eisenberger, M. A.; Sinibaldi, V.; Zabelina, Y.; Chen, T. L.; Grochow, L. B.; Donehower, R. C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 2001, 7, 3047-3055.
8. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
9. Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 2002, 64, 1079-1090.
10. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
11. Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone deacetylase inhibitors. Adv. Cancer Res. 2004, 91, 137-168.
12. Endres, M.; Meisel, A.; Biniszkiewicz, D.; Namura, S.; Prass, K.; Ruscher, K.; Lipski, A.; Jaenisch, R.; Moskowitz, M. A.; Dirnagl, U. DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 2000, 20, 3175-3181.
13. Qi, X.; Hosoi, T.; Okuma, Y.; Kaneko, M.; Nomura, Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 2004, 66, 899-908.
14. Ren, M.; Leng, Y.; Jeong, M.; Leeds, P. R.; Chuang, D. M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: Potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 2004, 89, 1358-1367.
15. Camelo, S.; Iglesias, A. H.; Hwang, D.; Due, B.; Ryu, H.; Smith, K.; Gray, S. G.; Imitola, J.; Duran, G.; Assaf, B.; Langley, B.; Khoury, S. J.; Stephanopoulos, G.; De Girolami, U.; Ratan, R. R.; Ferrante, R. J.; Dangond, F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164, 10-21.
16. Ferrante, R. J.; Kubilus, J. K.; Lee, J.; Ryu, H.; Beesen, A.; Zucker, B.; Smith, K.; Kowall, N. W.; Ratan, R. R.; Luthi-Carter, R.; Hersch, S. M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23, 9418-9427.
17. Hockly, E.; Richon, V. M.; Woodman, B.; Smith, D. L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P. A.; Steffan, J. S.; Marsh, J. L.; Thompson, L. M.; Lewis, C. M.; Marks, P. A.; Bates, G. P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 2041-2046.
18. McCampbell, A.; Taye, A. A.; Whitty, L.; Penney, E.; Steffan, J. S.; Fischbeck, K. H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15179-15184.
19. Steffan, J. S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B. L.; Kazantsev, A.; Schmidt, E.; Zhu, Y. Z.; Greenwald, M.; Kurokawa, R.; Housman, D. E.; Jackson, G. R.; Marsh, J. L.; Thompson, L. M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413, 739-743.
20. Gardian, G.; Browne, S. E.; Choi, D. K.; Klivenyi, P.; Gregorio, J.; Kubilus, J. K.; Ryu, H.; Langley, B.; Ratan, R. R.; Ferrante, R. J.; Beal, M. F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280, 556-563.
21. Minamiyama, M.; Katsuno, M.; Adachi, H.; Waza, M.; Sang, C.; Kobayashi, Y.; Tanaka, F.; Doyu, M.; Inukai, A.; Sobue, G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2004, 13, 1183-1192.
22. Tsankova, N. M.; Berton, O.; Renthal, W.; Kumar, A.; Neve, R. L.; Nestler, E. J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9, 519-525.
23. Gantt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 2006, 45, 6170-6178.
24. Hu, E.; Dul, E.; Sung, C. M.; Chen, Z.; Kirkpatrick, R.; Zhang, G. F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 2003, 307, 720-728.
25. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
26. Chen, B.; Petukhov, P. A.; Jung, M.; Velena, A.; Eliseeva, E.; Dritschilo, A.; Kozikowski, A. P. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1389-1392.
27. Kruger, A.; Soeltl, R.; Sopov, I.; Kopitz, C.; Arlt, M.; Magdolen, V.; Harbeck, N.; Gansbacher, B.; Schmitt, M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 2001, 61, 1272-1275.
28. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerhäuser, C.; Jung, M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in friend leukemic cells. J. Med. Chem. 2002, 45, 3296-3309.
29. Ratan, R. R.; Murphy, T. H.; Baraban, J. M. Oxidative stress induces apoptosis in embryonic cortical neurons. J. Neurochem. 1994, 62, 376-379.
30. Ryu, H.; Lee, J.; Olofsson, B. A.; Mwidau, A.; Dedeoglu, A.; Escudero, M.; Flemington, E.; Azizkhan-Clifford, J.; Ferrante, R. J.; Ratan, R. R. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4281-4286.
31. Morrison, B. E.; Majdzadeh, N.; Zhang, X.; Lyles, A.; Bassel-Duby, R.; Olson, E. N.; D'Mello, S. R. Neuroprotection by histone deacetylase-related protein. Mol. Cell. Biol. 2006, 26, 3550-3564.
32. Han, D.; Sen, C. K.; Roy, S.; Kobayashi, M. S.; Tritschler, H. J.; Packer, L. Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am. J. Physiol. 1997, 273, R1771-R1778.